Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare inborn error of metabolism characterized by persistent hypermethioninemia with increased levels of S-adenosylmethionine and S-adenosylhomocysteine which manifests with encephalopathy, severe global developmental delay, mild to severe liver dysfunction, hypotonia and facial dysmorphism (most significant is frontal bossing, macrocephaly, hypertelorism and depressed nasal bridge). Epileptic seizures, hypoglycemia and/or cardiac defects (pulmonary stenosis, atrial and/or ventricular septal defect, coarctation of the aorta) may be associated. Clinical picture may range from neurological symptoms only to multi-organ involvement.
Features include always present findings: Hypermethioninemia, Poor speech, Seizure, and Low muscle tone (hypotonia) and others; and very common findings: Elevated circulating S-adenosyl-L-homocysteine concentration, Prolonged prothrombin time, and Macrocephaly. 30 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Poor speech, Seizure, Multifocal epileptiform discharges |
Lab test results | 6 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Elevated circulating S-adenosyl-L-methionine concentration, Elevated circulating S-adenosyl-L-homocysteine concentration |
Muscles | 4 | Low muscle tone (hypotonia), Muscle weakness, Skeletal muscle atrophy |
Digestive system | 2 | Hepatic steatosis, Cholestasis |
Growth and development | 1 | Failure to thrive |
Arms and legs | 1 | Narrow foot |
Head and neck | 1 | Macrocephaly |
Bones and joints | 1 | Skeletal muscle atrophy |
Heart and blood vessels | 1 | Secundum atrial septal defect |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
ADK encodes adenosine kinase (362 aa). Adenosine kinase that mediates the phosphorylation of the purine nucleoside adenosine at the 5' position in an ATP-dependent manner: catalyzes phosphorylation of both unmodified and modified adenosines. Highest expression in Cells EBV-transformed lymphocytes (37.3 TPM) and Cells Cultured fibroblasts (34.1 TPM).
Adenosine kinase deficiency is caused by mutations in the ADK gene on chromosome 10.
The ADK protein participates in (2'-deoxy)adenosine + ATP = (d)AMP + ADP (ADK) pathway.
ADK is classified as a druggable target (Druggable Genome, Enzyme, and Kinase categories) with score 5.2.
13 pathogenic variants reported in ADK in ClinVar.
Genetic testing for ADK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for adenosine kinase deficiency has been reported in the published literature.
Phenotype severity distribution: 16 always present features, 3 very common features, 7 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for adenosine kinase deficiency.
42 publications have been identified in PubMed for adenosine kinase deficiency. Research spans Case Report / Case Series (36%), Epidemiology / Natural History (24%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 15 | 36% |
Disease patterns and progression | 10 | 24% |
Research summaries | 7 | 17% |
Laboratory research | 6 | 14% |
Testing and diagnosis research | 3 | 7% |
Clinical study results | 1 | 2% |
Al-Shahrani H (2026). [PMID: 41897354](https://pubmed.ncbi.nlm.nih.gov/41897354/). *Biomolecules*. [Epidemiology / Natural History]
Kido J (2026). [PMID: 42150437](https://pubmed.ncbi.nlm.nih.gov/42150437/). *Mol Genet Metab*. [Case Report / Case Series]
Ek M (2026). [PMID: 41514368](https://pubmed.ncbi.nlm.nih.gov/41514368/). *Genome Med*. [Epidemiology / Natural History]
Dudic A (2026). [PMID: 40824224](https://pubmed.ncbi.nlm.nih.gov/40824224/). *J Pediatr Orthop*. [Diagnostic / Biomarker]
Filipic M (2026). [PMID: 41623317](https://pubmed.ncbi.nlm.nih.gov/41623317/). *Mol Genet Metab Rep*. [Review / Meta-Analysis]
Triono A (2026). [PMID: 41543614](https://pubmed.ncbi.nlm.nih.gov/41543614/). *Neurogenetics*. [Review / Meta-Analysis]
Pan X (2026). [PMID: 41764152](https://pubmed.ncbi.nlm.nih.gov/41764152/). *J Mol Med (Berl)*. [Epidemiology / Natural History]
Cesur Baltacı HN (2026). [PMID: 41064050](https://pubmed.ncbi.nlm.nih.gov/41064050/). *Mol Syndromol*. [Case Report / Case Series]
Fridman H (2025). [PMID: 40374730](https://pubmed.ncbi.nlm.nih.gov/40374730/). *Nat Hum Behav*. [Epidemiology / Natural History]
Öz A (2025). [PMID: 39899686](https://pubmed.ncbi.nlm.nih.gov/39899686/). *J Pediatr Hematol Oncol*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 5:50 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adenosine kinase deficiency